Potential supervisors and their fields of research are featured below.
Scientia Professor Louisa Degenhardt, AO:Ìýl.degenhardt@unsw.edu.au
Epidemiology of illicit drug use (especially cannabis, amphetamines, cocaine and heroin); mortality among people who use drugs; drug use among young people; crime among opioid dependent people; injecting drug use; evidence for interventions to reduce harm among people who use drugs, including opioid agonist treatment; pharmaceutical opioid use, including by people who are living with chronic pain.Ìý
Associate Professor Rebecca McKetin:Ìýr.mcketin@unsw.edu.auÌý
Stimulant use; methamphetamine use and harms; methamphetamine psychosis; epidemiology; in-direct prevalence estimation; sentinel surveys of substance use; cohort studies; service coverage and barriers to care.Ìý
Associate Professor Amy Peacock:Ìýamy.peacock@unsw.edu.au
Trends in illicit drug use, harms, and market features; uptake and evaluation of strategies to reduce risk of drug-related harm (e.g., drug checking, drug alerts); alcohol consumption, risk-taking and harm, particularly among young people; and use of pharmaceutical opioids and strategies to reduce extra-medical use and harm. Projects draw on cross-sectional surveys, longitudinal surveys, administrative (including linked) health data (e.g., mortality, hospitalisations), and online data (e.g., darknet marketplace listings).Ìý
Scientia Associate Professor Natasa Gisev:Ìýn.gisev@unsw.edu.auÌý
Pharmaceutical opioid use and related harms; maximising treatment outcomes for people with opioid dependence, including those with co-morbid mental health disorders; quality use of opioids and psychotropic medicines, including evidence-based prescribing. Projects incorporate pharmacoepidemiological methods and the use of population-level linked administrative health data.ÌýÌý
Associate Professor Ryan Courtney:Ìýr.courtney@unsw.edu.auÌýÌý
Smoking cessation; tobacco smoking in low socio-economic status (SES) and disadvantaged populations; socio-economic inequalities and health behaviours and outcomes.Ìý
Dr Alys Havard:Ìýalys.havard@unsw.edu.auÌý
Drug use during pregnancy and related harms; use, effectiveness and safety of prescription medicines, including among specific populations such as pregnant women and people with cardiovascular disease; smoking cessation; data linkageÌý
Dr Winifred Asare-Doku:Ìýw.asaredoku@unsw.edu.auÌý
Mental health, behavioural health, dual diagnosis, suicide, alcohol & other drugs among populations such as the criminal justice system, young people, culturally and linguistically diverse people, and low - and middle-income countries. Workplace mental health programs, policy studies, intervention research, and evaluation of programs and services.Ìý
Dr Peter Gates:Ìýpeter.gates@unsw.edu.auÌý
Cannabis use and related harms; Evidence-base treatments for cannabis use disorder; Medicinal cannabis use; Community level drug and alcohol use and related harms: measurement and community-level prevention programsÌý
Dr Duong (Danielle) Tran:ÌýÌýDanielle.Tran@unsw.edu.auÌý
Medication use in pregnancy and associated health outcomes for mothers and babies; use of medicines and health services for chronic disease management; evaluation of health intervention program; cross-sectional and longitudinal surveys; health record linkages of electronic medical records, hospital admissions, claims and mortality data.Ìý
Dr Simon Clay:Ìýs.clay@unsw.edu.au
Qualitative research; gender diverse populations; substance dependency & health; methamphetamine use; opioid dependency; identity; social theory; drug trends; mental health; feminist & queer theory; public health policyÌý
Dr Rachel Sutherland:Ìýrachels@unsw.edu.auÌý
Trends in illicit drug use, harms, and market features; implementation, uptake and evaluation of strategies to reduce risk of drug-related harm (e.g., fentanyl test strips, drug alerts); injecting drug use. Projects draw on cross-sectional surveys, longitudinal surveys, and online data (e.g., darknet marketplace listings).Ìý
Dr Stella Settumba Stolk:Ìýs.nalukwago@unsw.edu.auÌý
Health Economics: Costs of interventions; Economic evaluations i.e. cost benefit analysis, cost-effectiveness analysis, and cost-utility analysis; valuing the benefits of interventions and policy options using stated preference methods i.e. discrete choice experiments and contingent valuations.Ìý
Dr Catherine Foley:Ìýc.foley@unsw.edu.au
Mental health, substance use, psychological trauma, and co-occurring conditions; development of collaborative, pragmatic models of care designed and driven by people who provide and/or receive health services; integration of research into clinical practice in regional, rural, and remote Australia.Ìý
